Eli Lilly chairman and CEO David Ricks joins 'Squawk on the Street' to discuss the path to becoming a trillion dollar company ...

Eli Lilly (LLY) heads into 2026 with GLP-1 pricing and competition risks; oral GLP-1 race heats up and downside looms.

Eli Lilly stays a Strong Buy as GLP-1 demand drives revenue/EPS beats, margin gains, and pipeline upside. Click here to read ...

It has made significant breakthroughs in the pharmaceutical space, and financial results have soared, with the stock price ...

NVO jumps nearly 19% in a month primarily on the FDA approval and launch of oral Wegovy, the first GLP-1 pill for obesity and ...

Novo Nordisk shares have surged on the back of its groundbreaking oral Wegovy approval, making it the first company to bring ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common ...

Eli Lilly is a well-established pharmaceutical company with a portfolio of products that consistently generate revenue and earnings. The company's top line has been growing at a good clip in recent ...

NVIDIA’s market is heating up, approaching the boiling point once again, as its long-term outlook swells and the valuation ...

Nomura analyst Cindy Park said Friday that Celltrion's 2026 revenue target of 5.3 trillion won supports a positive outlook, citing the company's plan to scale up its contract development and ...

Market analysts at Leerink Partners have issued a substantially more bullish outlook for Eli Lilly and Company, raising their price target for the pharmaceutical giant's stock. The firm increased its ...

As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate ...